Log in

NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

$22.66
+1.04 (+4.81 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$21.45
Now: $22.66
$22.83
50-Day Range
$21.38
MA: $24.10
$28.96
52-Week Range
$7.72
Now: $22.66
$29.20
Volume568,384 shs
Average Volume1.24 million shs
Market Capitalization$1.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.37
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Read More
Cytokinetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.6Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.94 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.87 million
Book Value($0.19) per share

Profitability

Net Income$-121,690,000.00
Net Margins-592.61%

Miscellaneous

Employees130
Market Cap$1.35 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable
$22.66
+1.04 (+4.81 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

How has Cytokinetics' stock been impacted by COVID-19 (Coronavirus)?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYTK shares have increased by 88.4% and is now trading at $22.66.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Cytokinetics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cytokinetics
.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Cytokinetics
.

How can I listen to Cytokinetics' earnings call?

Cytokinetics will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) released its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.16. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to analysts' expectations of $4.92 million.
View Cytokinetics' earnings history
.

What price target have analysts set for CYTK?

9 brokerages have issued 12-month target prices for Cytokinetics' shares. Their forecasts range from $20.00 to $59.00. On average, they anticipate Cytokinetics' share price to reach $37.22 in the next twelve months. This suggests a possible upside of 64.3% from the stock's current price.
View analysts' price targets for Cytokinetics
.

Has Cytokinetics been receiving favorable news coverage?

News coverage about CYTK stock has trended somewhat negative on Tuesday, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cytokinetics earned a news impact score of -1.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Cytokinetics
.

Are investors shorting Cytokinetics?

Cytokinetics saw a drop in short interest in June. As of June 30th, there was short interest totaling 7,720,000 shares, a drop of 6.3% from the June 15th total of 8,240,000 shares. Based on an average daily volume of 867,200 shares, the short-interest ratio is currently 8.9 days. Approximately 14.2% of the company's stock are sold short.
View Cytokinetics' Current Options Chain
.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include New York State Teachers Retirement System (0.20%), Comerica Bank (0.11%), Oregon Public Employees Retirement Fund (0.04%), ProShare Advisors LLC (0.03%), Granite Investment Advisors LLC (0.03%) and SG Americas Securities LLC (0.03%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics
.

Which institutional investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, UBS Group AG, Envestnet Asset Management Inc., Dupont Capital Management Corp, and First Citizens Bank & Trust Co.. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga.
View insider buying and selling activity for Cytokinetics
.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, Sigma Planning Corp, ProShare Advisors LLC, Comerica Bank, Granite Investment Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank , and Oregon Public Employees Retirement Fund. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics
.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $22.66.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $1.35 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

What is Cytokinetics' official website?

The official website for Cytokinetics is www.cytokinetics.com.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.